Product sheet

B-LCL-CDG3 | 302014

Description	B-LCL-CDG3 *PMM2* (CDG) PMM2-CDG EBV B . PMM2 -6- EBV B B-LCL-CDG3 *PMM2* . , PMM2 ,
Organism	
Tissue	
Disease	
Metastatic site	(EBV B-LCL;)
Applications	CDG , (: B), . , , HLA ,
Gender	
Ethnicity	
Morphology	
Cell type	B
Growth properties	,
Citation	B-LCL-CDG3(302014)
Biosafety level	2
NCBI_TaxID	9606
CellosaurusAccession	
Depositor	EMBL

B-LCL-CDG3 | 302014

GMO Status	GMO-S2: B-LCL (EBNA-1/-2/-3, LMP-1/-2) EBV . EBV 2
Viruses	: EBV
Culture Medium	RPMI 1640, w: 2.0mM , w: 2.0g/L NaHCO3(820700a)
Supplements	10% FBS
Subculturing	. 2 x 10^5 /ml , 1 x 10^5 ~ 5 x 10^5 /ml .
Fluid renewal	
Post-Thaw Recovery	Medium
Freeze medium	(FBS) + 10% DMSO , CM-1(Cytion 800100)
Thawing and Culturing Cells	1. . 2. -150°C , 3 . 3. 37°C 40~60 . 4. , 70% . 5. 8ml 15ml . 6. 300 x g 3 . 7. 10ml . T25 , T25 8. .

B-LCL-CDG3 | 302014

Incubation Atmosphere	37°C, 5% $_{CO2}$, .
Flask Coating	
Freezing Procedure	-78°C . .
Shipping Conditions	-78°C . .
Storage Conditions	-150°C -196°C . 80°C .
Sterility	PCR . , .